Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.

Hernández-Mijares A, Bañuls C, Gómez-Balaguer M, Bergoglio M, Víctor VM, Rocha M.

Eur J Clin Invest. 2013 Jun;43(6):549-56. doi: 10.1111/eci.12080. Epub 2013 Mar 26.

PMID:
23528141
2.

Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome.

Kim JJ, Chae SJ, Choi YM, Hwang KR, Song SH, Yoon SH, Kim SM, Ku SY, Kim SH, Kim JG, Moon SY.

Hum Reprod. 2013 May;28(5):1354-60. doi: 10.1093/humrep/det057. Epub 2013 Mar 10.

PMID:
23477907
3.

Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.

Zhang J, Fan P, Liu H, Bai H, Wang Y, Zhang F.

Hum Reprod. 2012 Aug;27(8):2484-93. doi: 10.1093/humrep/des191. Epub 2012 Jun 6.

PMID:
22674204
4.

Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS.

Roe A, Hillman J, Butts S, Smith M, Rader D, Playford M, Mehta NN, Dokras A.

J Clin Endocrinol Metab. 2014 May;99(5):E841-7. doi: 10.1210/jc.2013-3918. Epub 2014 Feb 10.

5.

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.

Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E.

Int J Clin Pract. 2009 Jan;63(1):56-62. doi: 10.1111/j.1742-1241.2008.01897.x.

PMID:
19125993
6.

Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.

Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E.

Hum Reprod. 2009 Sep;24(9):2286-92. doi: 10.1093/humrep/dep121. Epub 2009 May 19.

PMID:
19454589
7.
8.

Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters.

Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N.

Clin Endocrinol (Oxf). 2001 Apr;54(4):447-53.

PMID:
11318779
9.

Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.

Yilmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Törüner F, Paşaoğlu H.

Gynecol Endocrinol. 2005 May;20(5):258-63.

PMID:
16019370
10.

Metabolic dysfunction in obese Hispanic women with polycystic ovary syndrome.

Sam S, Scoccia B, Yalamanchi S, Mazzone T.

Hum Reprod. 2015 Jun;30(6):1358-64. doi: 10.1093/humrep/dev073. Epub 2015 Apr 8.

11.

A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.

Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS.

J Clin Endocrinol Metab. 2008 Feb;93(2):470-6. Epub 2007 Dec 4.

PMID:
18056772
12.

Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS.

Phelan N, O'Connor A, Kyaw-Tun T, Correia N, Boran G, Roche HM, Gibney J.

J Clin Endocrinol Metab. 2010 Aug;95(8):3933-9. doi: 10.1210/jc.2009-2444. Epub 2010 Jun 2.

PMID:
20519354
13.

Hypoadiponectinemia: a useful marker of dyslipidemia in women with polycystic ovary syndrome.

Chang CY, Chen MJ, Yang WS, Yeh CY, Ho HN, Chen SU, Yang YS.

Taiwan J Obstet Gynecol. 2012 Dec;51(4):583-90. doi: 10.1016/j.tjog.2012.09.014.

14.

Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.

Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoğlu G, Yesilkaya E, Hasanoğlu A.

Clin Endocrinol (Oxf). 2007 Jul;67(1):129-34. Epub 2007 Apr 25.

PMID:
17465999
15.

Lipid and lipoprotein profile in women with polycystic ovary syndrome.

Macut D, Panidis D, Glisić B, Spanos N, Petakov M, Bjekić J, Stanojlović O, Rousso D, Kourtis A, Bozić I, Damjanović S.

Can J Physiol Pharmacol. 2008 Apr;86(4):199-204. doi: 10.1139/Y08-014.

PMID:
18418429
16.

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

Rizzo M, Berneis K, Carmina E, Rini GB.

Am J Obstet Gynecol. 2008 Jan;198(1):28.e1-5. doi: 10.1016/j.ajog.2007.09.014. Review.

PMID:
18166299
17.

Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women.

Maitra A, Pingle RR, Menon PS, Naik V, Gokral JS, Meherji PK.

Int J Fertil Womens Med. 2001 Sep-Oct;46(5):271-7.

PMID:
11720200
18.

Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.

Castelo-Branco C, Steinvarcel F, Osorio A, Ros C, Balasch J.

Gynecol Endocrinol. 2010 Oct;26(10):736-42. doi: 10.3109/09513590.2010.481025.

PMID:
20569105
19.

Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors.

Rocha MP, Marcondes JA, Barcellos CR, Hayashida SA, Curi DD, da Fonseca ÂM, Bagnoli VR, Baracat EC.

Gynecol Endocrinol. 2011 Oct;27(10):814-9. doi: 10.3109/09513590.2010.508852. Epub 2010 Sep 1.

PMID:
20807166
20.

LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome.

Doi SA, Abbas JM, Parkinson L, Chakraborty J, Akanji AO.

Am J Clin Pathol. 2008 May;129(5):802-10. doi: 10.1309/E7EGTTVCRFVBA7EC.

PMID:
18426742

Supplemental Content

Support Center